Media

  • We're thrilled to announce the successful filing of the USDMF for Sitagliptin Phosphate Monohydrate! This milestone represents a significant step

    Jan 23, 2024

    read more

  • Ami Lifesciences family blissfully celebrates the divine homecoming of Lord Ram in Ayodhya with heartfelt prayers and Shobha Yatra.

    Jan 23, 2024

    read more

  • We are excited to announce the US DMF submission of Mirogablin Besylate to the US FDA.

    Jan 01, 2024

    read more

  • As we say goodbye to 2023, we pause to reflect on our team's accomplishments. This year has prove.

    Jan 01, 2024

    read more

  • We will be exhibiting at CPHI & PMEC India PMEC at India Expo Centre & Mart, Greater Noida on November 28-30, 2023.

    Nov 22, 2023

    read more

  • You are cordially invited to attend CPHI Barcelona 2023 and meet our emerging markets team. We're thrilled to have you in this exclusive space

    Oct 17, 2023

    read more

  • Mark your calendar to connect with our team at CPHI Barcelona, 2023. Seize the chance to launch ground-breaking collaborative projects.

    Oct 17, 2023

    read more

  • Join us at CPHI Barcelona from October 24th to 26th!!! Team Ami is excited to welcome you to this vibrant platform and world's

    Oct 17, 2023

    read more

  • At CPhI Worldwide 2023, the pharmaceutical industry will congregate in Barcelona, and Ami Lifesciences will be leading the charge.

    Oct 11, 2023

    read more

  • We are thrilled to announce that the USDMF for Finerenone has been submitted to the USFDA; this is the first USDMF for Finerenone API from an Indian

    Sep 29, 2023

    read more

  • Congratulations to team Ami Lifesciences for being shortlisted as a finalist for the Regulatory Achievement of the Year award at the Global Generics

    Sep 28, 2023

    read more

  • We will be exhibiting at CPHI Barcelona, 2023, the world's leading pharmaceutical and healthcare exhibition!
    Meet our team at booth no. 81C40 during the event.

    Sep 20, 2023

    read more

  • We are very grateful to all our clients and visitors for their time and meaningful discussion during the meetings at PharmaConex 2023.

    Sep 08, 2023

    read more

  • It's time to say CPhI Korea 2023
    Our team is grateful to all the customers and visitors for the meaningful meetings and discussions at our booth.

    Sep 01, 2023

    read more

  • Ami Lifesciences is pleased to announce that it will be exhibiting at CPHI Korea at COEX in Seoul from August 30 to September 1 at booth No. G38B.

    Sep 01, 2023

    read more

  • We are delighted to announce the successful CADIFA submission of Bempedoic Acid to ANVISA, Brazil. For this API, we are fully backward-integrated

    Sep 01, 2023

    read more

  • Ami Lifesciences will be exhibiting at Pharmaconex 2023, to be held from September 3 to 5, 2023 at the Egypt International Exhibition Centre in Cairo.

    Aug 28, 2023

    read more

  • Ami Lifesciences is pleased to announce that it will be exhibiting at CPHI Korea from August 30 to September 1 at COEX in Seoul at booth No. G38B

    Aug 22, 2023

    read more

  • We are thrilled to announce Ami Lifesciences being the Highest USDMF filer (#14) in H-1 2023 timeframe Globally.

    Aug 21, 2023

    read more

  • We are delighted to announce that the USDMF for Daprodustat API has been filed with the US FDA.

    June 30, 2023

    read more

  • Yoga is the fountain of youth. It's exercise, meditation, and philosophy rolled into one.

    June 26, 2023

    read more

  • Sneak peek of our team at China CPHI, connecting with clients, business partners

    June 26, 2023

    read more

  • We are happy to be back in China and exhibiting at CPHI China from June 19-21, 2023.

    June 19-21, 2023

    read more

  • CPHI North America was a success for Ami Lifesciences Pvt Ltd. We appreciate our clients and guests stopping

    April 25 to 27, 2023.

    read more

  • We are exhibiting at CPHI North America, and you are welcome to visit the Ami Lifesciences

    April 25 to 27, 2023.

    read more

  • We are pleased to inform that we are now EcoVadis Certified, the most widely recognized international

    20 April 2023

    read more

  • We are excited to be at CPhI Japan (19-21 April 2023). It will be a pleasure to meet our customers

    10 April 2023

    read more

  • We will be exhibiting at the CPHI North America Exhibition in Pennsylvania from April 25th to 27th, 2023.

    10 April 2023

    read more

  • The USDMF for Empagliflozin API submitted to the USFDA. Our expert team created and scaled up a lean process to assist our formulation partners

    27 Mar 2023

  • Ami Lifesciences had a very successful DCAT Week, with significant customer meetings and anticipating an incredible path forward.

    27 Mar 2023

  • We are pleased to inform you that the USDMF for Edoxaban API has been submitted to the USFDA. Based on our process expertise

    27 Mar 2023

    read more

  • Mr Varad Nabar, AVP Marketing, will attend DCAT (Drug, Chemical & Associated Technologies Association) Week 2023 in New York

    20 - 23 Mar 2023

    read more

  • The DCAT (Drug, Chemical & Associated Technologies Association) week is approaching; come meet us and learn more about Ami Lifesciences

    20 - 23 Mar 2023

    read more

  • Our CEO, Amit Kaptain, will be in New York from March 20th to 23rd for DCAT (Drug, Chemical & Associated Technologies Association) Week 2023.

    20 - 23 Mar 2023

    read more

  • It gives us great pleasure to announce that the USDMF for Sacubitril Sodium has been submitted to the USFDA. With an innovative development strategy, our team of experts

    20 Mar 2023

    read more

  • Our innovation efforts have been validated today when our R&D team received Excellence in Research and Development" award.

    20 Mar 2023

    read more

  • We are pleased to inform you that Sacubitril Valsartan's USDMF has been successfully submitted to the USFDA. Our process experts developed Sacubitril Valsartan

    09 Mar 2023

    read more

  • We are pleased to announce that the USDMF for Desvenlafaxine Succinate has been submitted to the USFDA.

    08 Mar 2023

    read more

  • We are glad to share that the US DMF for Sevelamer Hydrochloride was successfully submitted to the USFDA. We have a distinctive advantage

    02 Mar 2023

    read more

  • We are happy to announce our USDMF filing of Dapagliflozin Amorphous to the USFDA.

    02 Mar 2023

    read more

  • We are extremely happy to share the successful filling of Febuxostat USDMF with the USFDA.

    18 Feb 2023

    read more

  • We are happy to share that the US DMF for Sevelamer Carbonate was successfully submitted to the USFDA.

    17 Feb 2023

    read more

  • We are delighted to announce that the USDMF for Tadalafil was successfully submitted to the USFDA.

    17 Feb 2023

    read more

  • We'll be at DCAT (Drug, Chemical & Associated Technologies Association) 2023

    17 Feb 2023

    read more